Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 17/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686282 | 0.92 | PTGER1 (0.70) | PTGER1CYP2C9 | |
| SCHEMBL4686667 | 0.90 | PTGER1 (0.56) | PTGER1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4684051 | 0.89 | PTGER1 (0.74) | PTGER1CYP1A2CYP2C9CYP2C19MRGPRX4 | |
| SCHEMBL4680467 | 0.88 | PTGER1 (0.83) | PTGER1MRGPRX4 | |
| SCHEMBL4683305 | 0.87 | PTGER1 (0.58) | PTGER1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4683334 | 0.85 | PTGER1 (0.78) | PTGER1MRGPRX4 | |
| SCHEMBL5469113 | 0.83 | PTGER1 (1.00) | PTGER1MRGPRX4 | |
| SCHEMBL4683785 | 0.82 | PTGER1 (0.58) | PTGER1 | |
| SCHEMBL4685275 | 0.80 | PTGER1 (0.62) | PTGER1 | |
| SCHEMBL4680869 | 0.78 | PTGER1 (0.59) | PTGER1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675832-B1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | EP | claimed |
| EP-1675832-B1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-20070060596-A1 | Heterocyclyl compounds | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
| US-20070060596-A1 | Heterocyclyl compounds | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060596-A1 | Heterocyclyl compounds | F9, F12, CYP2C9 | PTGER1 1257/4885CYP1A2 208/4885CYP3A4 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.